Does a targeting ligand influence nanoparticle tumor localization or uptake?

Trends in Biotechnology

Volumn 26, Issue 10, 2008, Pages 552-558

  Pirollo, Kathleen F ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE COMPOUNDS; ETHYLENE; ETHYLENE GLYCOL; GLYCOLS; LIGANDS; NANOPARTICLES; NANOSTRUCTURES; POLYETHYLENE GLYCOLS;

BIO-DISTRIBUTION; IN-VIVO; NANO COMPLEX; TUMOR LOCALIZATION;

TUMORS;

DOXORUBICIN; LIGAND; LIPOSOME; MACROGOL; NANOPARTICLE;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION; HUMAN; IN VIVO STUDY; MEMBRANE PERMEABILITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DESIGN; HUMANS; NANOPARTICLES; NEOPLASMS; PERMEABILITY; POLYETHYLENE GLYCOLS;

EID: 51249122212     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2008.06.007     Document Type: Article

References (41)

1. De Paula D., et al. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13 (2007) 431-456
2. Meyer M., and Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum. Gene Ther. 17 (2006) 1062-1076
3. Li S.D., and Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther. 13 (2006) 1313-1319
4. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451-1458
5. Hamidi M., et al. Pharmacokinetic consequences of pegylation. Drug Deliv. 13 (2006) 399-409
6. Owens III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
7. Allen T.M., et al. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 6 (2006) 513-523
8. Modi S., et al. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr. Pharm. Des. 12 (2006) 4785-4796
9. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986) 6387-6392
10. Iyer A.K., et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006) 812-818
11. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001) 189-207
12. Garanger E., et al. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem. 7 (2007) 552-558
13. de Bruin K., et al. Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol. Ther. 15 (2007) 1297-1305
14. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94 (2005) 2135-2146
15. Xu L., et al. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 10 (1999) 2941-2952
16. Daniels T.R., et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121 (2006) 144-158
17. Dass C.R., and Choong P.F. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J. Control Release 113 (2006) 155-163
18. Xu L., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med. 7 (2001) 723-734
19. Xu L., et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1 (2002) 337-346
20. Pirollo K.F., et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17 (2006) 117-124
21. Pirollo K.F., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67 (2007) 2938-2943
22. Pirollo K.F., et al. Immunoliposomes: a targeted delivery tool for cancer treatment. In: Curiel D.T., and Douglas J.T. (Eds). Vector Targeting for Therapeutic Gene Delivery (2002), Wiley 33-62
23. Bartlett D.W., et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15549-15554
24. Kirpotin D.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
25. Wu A.M., et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8495-8500
26. Sundaresan G., et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44 (2003) 1962-1969
27. Kircheis R., et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8 (2001) 28-40
28. Yu W., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res. 32 (2004) e48
29. Cheng J., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28 (2007) 869-876
30. Hussain S., et al. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 6 (2007) 3019-3027
31. Pun S.H., et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3 (2004) 641-650
32. 18F]FDG PET in clinical oncology. Lancet Oncol. 8 (2007) 822-830
33. Weber W.A., and Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference?. J. Nucl. Med. 48 Suppl. 1 (2007) 36S-44S
34. Zaidi H. Recent developments and future trends in nuclear medicine instrumentation. Z. Med. Phys. 16 (2006) 5-17
35. 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med. 49 (2008) 103-111
36. Maeda H., et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3 (2003) 319-328
37. Cao Y., et al. The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res. 66 (2006) 8912-8917
38. Khalid M.N., et al. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 23 (2006) 752-758
39. Fang C., et al. In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 27 (2006) 27-36
40. Yu W., et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther. 11 (2004) 1434-1440
41. Gabizon A.A., et al. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16 (2006) 175-183